As life sciences organizations look to get more value from clinical trial data, the reuse of Individual Human Data (IHD) is becoming a priority across R&D and clinical operations. IHD can support everything from patient targeting and stratification to more accurate trial outcome simulation, especially as AI enables new ways to analyze and apply sensitive datasets. Yet, responsible reuse remains difficult, because it must continuously uphold informed consent, jurisdiction specific requirements, and strong safeguards against re identification, particularly in rare disease contexts.